MedTrace Logo

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

NCT00691158 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-12-16

No results posted yet for this study

Summary

The purpose of this study is to identify how certain parts of the brain that help control body weight respond to an infusion of hormones called leptin and amylin.

Conditions

Interventions

DRUG

Pramlintide (Amylin)

4.7 mls of Amylin 15mcg/ml IV bolus.

DRUG

Placebo (Normal Saline)

4.7 mls normal saline IV bolus x1

DRUG

2 Metreleptin

Receive .06mg/kg of metreleptin IV bolus x1

DRUG

Leptin plus Pramlintide

receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Jonathan Q. Purnell, M.D. · OHSU - Center for the Study of Weight Regulation

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691158 on ClinicalTrials.gov